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Abstract: Anemia is highly prevalent in patients with lung cancer,
often occurring at baseline and frequently exacerbated as a result of
treatment with platinum-based chemotherapy. Anemia has been
shown to have a negative effect on quality of life in patients with
lung cancer, and additional data indicate that decreases in hemoglo-
bin in these patients are associated with impaired survival. Multiple
clinical studies have demonstrated that treatment of anemia with
erythropoietic agents in patients with lung cancer results in a
significant increase in hemoglobin, decrease in transfusions, and
improvement in quality of life. Ongoing research is evaluating
whether erythropoietic therapy can reduce cognitive impairment
associated with lung cancer, cytotoxic therapy, and anemia. Despite
the known adverse effects of anemia and the established benefits of
erythropoietic therapy in anemic patients with lung cancer, more
than half of these patients do not receive any anemia treatment. The
purpose of this review is to report results of the European Cancer
Anaemia Survey that describe the prevalence of anemia in patients
with lung cancer, to review the major studies evaluating the clinical
outcomes of erythropoietic therapy in patients with lung cancer, to
discuss the recent safety concerns regarding the use of erythropoietic
agents in patients with cancer treated to high hemoglobin levels, and
to describe various novel therapeutic applications of erythropoietic
agents in lung cancer.
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(J Thorac Oncol. 2006;1: 716–725)
Lung cancer is the most common cancer worldwide, with aprevalence nearly threefold greater in men than in wom-
en.1 Cancer-related or cancer treatment–related anemia oc-
curs frequently in patients with lung cancer,2,3 with one
comprehensive review reporting incidences of anemia (he-
moglobin [Hb] 12 g/dL) and severe anemia (Hb 8 g/dL)
as high as 100% and 55%, respectively, in patients with lung
cancer receiving chemotherapy.2 One major factor contribut-
ing to anemia in patients with lung cancer is the use of
platinum-based chemotherapy, a regimen that results in clin-
ically meaningful decreases in Hb,2 as first-line chemother-
apy for lung cancer.2,4,5 The severity of anemia in these
patients is dependent on disease stage, as well as the duration,
type, and intensity of chemotherapy.6 The National Cancer
Institute (NCI) and the World Health Organization (WHO)
have established criteria for the classification of the severity
of anemia related to cancer therapy (Table 1).2 These criteria
each grade the severity of anemia on a 0 (within normal
limits) to 4 (life-threatening) scale.
Anemia in patients with cancer contributes to fatigue
and other symptoms that can impair health-related quality of
life (QOL).7–9 The adverse consequences of anemia may be
particularly important in lung cancer because these patients
have been shown to have higher incidences of anemia and
transfusion for anemia than patients with other solid tu-
mors2,10,11 and often have comorbid conditions, such as car-
diovascular and pulmonary disease,12 that may worsen ane-
mia symptoms and impair tolerance of Hb decreases. In
open-label, community-based studies as well as a random-
ized, double-blind, placebo-controlled trial, treatment of ane-
mia with recombinant human erythropoietin (epoetin alfa) in
patients with cancer receiving chemotherapy with or without
radiation therapy produced significant increases in Hb, sig-
nificant decreases in transfusion requirements, and significant
and clinically meaningful improvements in QOL.13–19 In-
creases in Hb in these studies were associated with improve-
ments in QOL,15–20 and further studies showed the greatest
incremental improvement in QOL occurred when Hb in-
creased from 11 to 12 g/dL during epoetin alfa therapy.21,22
Other investigators have suggested that anemia is an inde-
pendent prognostic factor for survival in patients with lung
cancer.23–26 Therefore, strategies to correct anemia in these
patients may be beneficial in improving therapeutic outcomes
in addition to improving QOL.
The purpose of this review is to report the prevalence of
anemia in patients with lung cancer, to review the major
studies evaluating the clinical outcomes of erythropoietic
therapy in patients with lung cancer, to discuss the recent
safety concerns of erythropoietic agents in patients with
cancer treated to high Hb levels, and to describe the potential
role of erythropoietic therapy in attenuating cognitive impair-
ment in patients with lung cancer.
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PREVALENCE OF ANEMIA IN LUNG CANCER:
THE EUROPEAN CANCER ANAEMIA SURVEY
(ECAS)
The ECAS was a prospective, observational, epidemi-
ologic survey that assessed the prevalence, incidence, and
treatment of anemia (Hb 12 g/dL); risk factors for devel-
oping anemia; and the relationship between anemia and
WHO performance status in European patients with cancer.3
The survey was conducted during 2001 in about 750 centers
in 24 countries; patients were followed for as long as 6
months. Of 15,367 enrolled patients, 2176 had lung cancer
and provided data for baseline characteristics (i.e., the enroll-
ment population) (median age, 62 years; 76% male; 70% with
WHO performance status 0 or 1).27 Of the 2176 patients, 119
were excluded from further analysis because of inconsistent
diagnosis and treatment; thus, 2057 patients with lung cancer
were included in the assessable population. Of the assessable
population, 1900 patients had at least one evaluation following
enrollment and were included in the analysis population.27
Of the enrollment population (n  2176), 63% of
patients overall had newly diagnosed lung cancer and 53%
had never received treatment for lung cancer.27 In the assess-
able population (n  2057), 2002 patients had assessable
baseline Hb data; 38% (753/2002) of these patients were
anemic at enrollment. Baseline anemia was present in 31% of
untreated patients, 32% of patients receiving radiation ther-
apy, 39% of patients receiving chemotherapy, and 50% of
patients receiving concomitant chemotherapy/radiation ther-
apy. In patients with anemia at enrollment, lower baseline Hb
was significantly correlated (Spearman’s r  0.124; p 
0.001) with poorer baseline WHO performance status.27
Of the 1900 patients included in the analysis popula-
tion, 1462 (77%) developed anemia at some point during the
survey.27 Anemia was most prevalent among patients receiv-
ing chemotherapy (956/1147; 83%) or nonconcomitant com-
bination chemotherapy/radiation therapy (342/407; 84%)
(Figure 1). Of the 1462 patients who developed anemia
during the survey, Hb nadirs were less than 9.0 g/dL in 21%
of patients and 9.9 g/dL or less in 46% of patients. Of the
1147 patients who underwent chemotherapy during the sur-
vey, anemia occurred slightly more frequently among pa-
tients receiving platinum chemotherapy (692/818; 85%) com-
pared with nonplatinum chemotherapy (264/329; 80%). With
respect to anemia treatment, 53% (507/956) of anemic pa-
tients undergoing chemotherapy received no anemia treat-
ment, 24% received erythropoietic therapy (mean Hb at
initiation, 9.1 g/dL), 18% received red blood cell transfusion
(mean Hb at initiation, 8.5 g/dL), and 5% received iron only.
Logistic analysis revealed that the risk of developing anemia
in these lung cancer patients was doubled by treatment with
platinum-based chemotherapy (adjusted odds ratio  2.1;
p  0.0002) or by being female (adjusted odds ratio  1.7;
p  0.0129).27
Of the patients who were not anemic or receiving
anemia treatment at enrollment and who initiated cancer
treatment and underwent at least two cycles of therapy during
the survey (total n  485 [chemotherapy, n  417; radiation
therapy, n  55]), 71% became anemic during the survey.27
The incidence of anemia in these patients was 80% for those
receiving chemotherapy, 31% for those receiving concomi-
tant chemotherapy/radiation therapy, and 15% for those re-
TABLE 1. National Cancer Institute (NCI) and the World
Health Organization (WHO) Toxicity Criteria for Anemia2
Severity NCI (Hb, g/dL) WHO (Hb, g/dL)
Grade 0 WNL 11.0
Grade 1 (mild) 10.0 to WNL 9.5–10.9
Grade 2 (moderate) 8.0–10.0 8.0–9.4
Grade 3 (serious/severe) 6.5–7.9 6.5–7.9
Grade 4 (life threatening) 6.5 6.5
Hb, hemoglobin; NCI, National Cancer Institute; WHO, World Health Organiza-
tion; WNL, within normal limits.
Adapted with permission from Pohl GMI, Ludwig H. Supportive treatment for
anemic cancer patients. Wien Med Wochenschr 2004;154:226–234.
FIGURE 1. Frequency of anemia by cancer
treatment during the European Cancer Anaemia
Survey.27 CT, chemotherapy; RT, radiation ther-
apy. *Analysis population, n  1900 (missing
data for two patients). Combination CT/RT refers
to administration of CT and RT at different times
(i.e., not concomitantly).
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ceiving radiation therapy. In addition, the incidence of ane-
mia was 81% (334/415) in patients receiving platinum
chemotherapy and 20% (81/415) in patients receiving non-
platinum chemotherapy, and the incidence of anemia in-
creased with successive cycles of platinum chemotherapy. In
patients who received no treatment for their anemia, the mean
times to Hb less than 12 g/dL and Hb less than 11 g/dL were
similar between patients receiving platinum versus nonplati-
num chemotherapy (7.7 versus 7.1 weeks and 9.6 versus 9.4
weeks, respectively).27
A separate analysis identified significant predictors of
anemia using a multivariate logistic regression model in 2070
patients in the overall ECAS population who were not anemic
at the start of chemotherapy and who initiated and received
two or more cycles of chemotherapy during the survey.28 The
study used clinical risk scores (CRS) to determine the overall
risk of developing anemia. The model found the following
factors to be significant independent predictors of anemia: Hb at
enrollment (12.9 g/dL for females and13.4 g/dL for males)
(CRS  13), lung/gynecologic cancer versus gastrointestinal/
colorectal cancer (CRS  12), any other tumor type versus
gastrointestinal/colorectal cancer (CRS 8), intended treatment
with platinum chemotherapy (CRS  7), and female versus
male gender (CRS  4). Because patients with lung cancer
would have an initial CRS of 12, any additional risk factor, such
as female gender or treatment with platinum chemotherapy,
would increase the risk of anemia to a high probability.28
The data from ECAS indicate a high prevalence of
anemia but less than optimal management of anemia in
patients with lung cancer. Together, these findings underscore
the need for better anemia management in this high-risk
population.
CLINICAL OUTCOMES OF ERYTHROPOIETIC
THERAPY IN PATIENTS WITH LUNG CANCER
Anemia Treatment in Lung Cancer
Erythropoietic agents, also known as erythropoietic
stimulating agents, approved in the United States and Europe
for the treatment of chemotherapy-related anemia in patients
with nonmyeloid malignancies include epoetin alfa (Procrit
[United States]; Eprex, Erypo, Epoxitin, Globuren, Epopen
[Europe]), darbepoetin alfa (Aranesp), and epoetin beta (Neo-
Recormon). Current evidence-based guidelines for the treat-
ment of chemotherapy-related anemia issued by the Ameri-
can Society of Clinical Oncology (ASCO) and the American
Society of Hematology (ASH) recommend treatment with an
erythropoietic agent if Hb decreases to less than 10 g/dL.29
Similarly, guidelines issued by the U.S. National Compre-
hensive Cancer Network (NCCN) and the European Organi-
sation for Research and Treatment of Cancer (EORTC) rec-
ommend treatment if Hb decreases to 11 g/dL or less.30,31
Clinical studies have demonstrated that treatment of anemia
with erythropoietic agents in patients with lung cancer sig-
nificantly improves hematologic outcomes and decreases
transfusion requirements.14,32–34 In a retrospective analysis of
anemic patients with lung cancer who participated in three
large, multicenter, community-based studies,15–17 mean Hb
significantly (p  0.0001) increased after 4 weeks of treat-
ment with epoetin alfa and continued to increase throughout
the 16-week study.14 The overall mean increase in Hb from
baseline (9.4 g/dL) to final measurement was 1.9 g/dL (p 
0.0001), and the proportion of patients requiring transfusions
decreased from 18.5% at baseline to 6.1% at month 4 (p 
0.001). Significant (p  0.0001) improvements in QOL from
baseline to final measurement were observed in all three
studies (Figure 2). In addition, all studies demonstrated a
significant (p  0.0001), positive correlation between in-
creases in Hb and improvements in QOL.14
An additional phase III, randomized, double-blind, pla-
cebo-controlled study evaluated the efficacy of darbepoetin
alfa (2.25 mcg/kg subcutaneously [SC] once weekly) in
treating anemia in patients with lung cancer receiving multi-
cycle platinum-containing chemotherapy.33 Eligible patients
had small cell lung cancer (SCLC) or non-small cell lung
cancer (NSCLC), baseline Hb 11 g/dL or less and were
scheduled to receive at least 12 additional weeks of chemo-
n =
FIGURE 2. Mean change in Linear Analog Scale
Assessment (LASA) scores from baseline to final
measurement in patients with lung cancer.14
QOL, quality of life. *p  0.0001 versus baseline
(adjusted for multiple comparisons). Adapted
from Clinical Lung Cancer, volume 3. Crawford J,
Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ,
Glaspy J. Clinical benefits of epoetin alfa therapy
in patients with lung cancer. Pages 180–190.
Copyright 2002. Used with permission from:
Cancer Information Group.
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therapy. In the darbepoetin alfa (n  156) and placebo (n 
158) groups, respectively, the majority of patients had
NSCLC (69% and 72%) and mean baseline Hb was similar
between groups (10.3 g/dL and 9.9 g/dL, respectively). The
proportion of patients transfused from week 5 to the end of
treatment (primary endpoint) was significantly lower for
patients treated with darbepoetin alfa compared with placebo
(27% versus 52%; p 0.001), as was the mean number of red
blood cell units transfused (0.67 versus 1.92; p  0.001). A
hematopoietic response (Hb increase 2 g/dL or Hb 12 g/dL
in the absence of transfusion within the previous 28 days) was
achieved in 66% of darbepoetin alfa patients compared with
only 24% of placebo patients (p  .001). Improvements in
QOL also significantly favored the darbepoetin alfa group.
The darbepoetin alfa and placebo groups did not differ
significantly with respect to median progression-free survival
(22 versus 20 weeks), overall mortality (59% versus 69%), or
the median duration of survival (46 weeks versus 34 weeks)
at 1-year follow up.33
Hb levels less than 12 g/dL have been shown to be
associated with suboptimal QOL in patients with cancer
receiving chemotherapy,21,22 and NCCN guidelines for the
treatment of chemotherapy-related anemia recommend treat-
ment with an erythropoietic agent to achieve a target Hb level
of 12 g/dL.31 Despite these observations, mild anemia (Hb
10–12 g/dL) is often not routinely treated. Recent open-label
studies in patients with breast cancer35 and hematologic
malignancies36 have shown that treatment with epoetin alfa in
patients with mild anemia maintains Hb and prevents QOL
deterioration during chemotherapy.
A study evaluating treatment of mild anemia in patients
with NSCLC has also been recently completed. This open-
label, randomized, multicenter, 16-week study in patients
with advanced NSCLC scheduled to receive first-line chemo-
therapy evaluated the safety and efficacy of immediate versus
delayed treatment of anemia with epoetin alfa.37 The primary
endpoint was the between-group comparison of changes in
Linear Analog Scale Assessment (LASA) scores from base-
line to weeks 9/10 and week 16. Eligible patients had che-
motherapy-naı¨ve stage IIIB/IV NSCLC, baseline Hb 11 to
15 g/dL or more unrelated to transfusion within 30 days, an
Eastern Cooperative Oncology Group (ECOG) performance
status 0 to 2, and were scheduled to receive at least 8 weeks
of chemotherapy. Patients received either epoetin alfa 40,000
IU SC once weekly at the start of chemotherapy (immediate
group) or no epoetin alfa unless Hb decreased to 10 g/dL or
less (delayed group) (Figure 3). At the time of preliminary
analysis, 106 patients in the immediate group and 105 in the
delayed group were assessable for efficacy (Table 2). Plati-
num-containing chemotherapy was received by 80% and 78%
of patients in the immediate and delayed groups, respectively,
and patients in each group received chemotherapy for a mean
of 10.6 weeks. Mean LASA score decreased in both groups;
however, scores were significantly lower in the delayed group
at weeks 9/10 (p  0.01) (Figure 4). A total of 18% of
patients in the immediate group and 44% of patients in the
delayed group had Hb decrease to less than 10 g/dL (p 
0.0001); baseline Hb less than 13 g/dL was a significant
predictor of Hb decreasing to less than 10 g/dL in the delayed
group (odds ratio  0.45; p  0.049). Fewer patients with
anemia in the immediate compared with the delayed group
were transfused during the study (12.3% versus 21.0%; p 
0.089). Overall, 46% of patients in the delayed group re-
ceived epoetin alfa (median time to first dose of epoetin alfa,
5.7 weeks). Patients in the immediate group maintained Hb
throughout the study, whereas delayed patients (including 48
patients who received epoetin alfa) experienced decreases in
Immediate group Delayed group
FIGURE 3. Treatment schema of a randomized, multicenter
study evaluating the safety and efficacy of immediate versus
delayed treatment of anemia with once-weekly epoetin alfa
in patients with NSCLC receiving first-line chemotherapy.37
NSCLC, non-small cell lung cancer; SC, subcutaneously;
QW, once weekly; Hb, hemoglobin.
TABLE 2. Demographics and Baseline Characteristics of
Patients Enrolled in a Randomized, Multicenter Study
Evaluating the Safety and Efficacy of Immediate versus
Delayed Treatment of Anemia with Once-Weekly Epoetin
Alfa in Patients with NSCLC Receiving First-Line
Chemotherapy37
Characteristic
Immediate group
(n  106)
Delayed group*
(n  105)
Age, y, mean  SD 62.3  11.0 62.7  10.6
Gender, no. (%)
Male 67 (63) 57 (54)
Female 39 (37) 48 (46)
Race, no. (%)
White 73 (69) 86 (82)
Black 25 (24) 14 (13)
Other 8 (8) 5 (5)
ECOG performance status, no. (%)†
0–1 101 (94) 84 (79)
2 6 (6) 21 (20)‡
Hb, g/dL, mean  SD 13.1  1.0 13.0  1.2
* Includes all control patients, including 48 patients who received epoetin alfa
because Hb decreased to less than 10 g/dL.37
† P  0.009 for immediate versus delayed group.
‡ Includes one patient with ECOG performance status 3.
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group;
Hb, hemoglobin.
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Hb until study end. Significant between-group differences in
Hb were observed as early as week 3 (p  0.0001), and
delayed patients had a decrease in Hb of more than 1 g/dL by
week 4. Tumor response and survival were similar between
groups.37 Final results from this study will provide further
insight into whether treating patients with NSCLC and mild
anemia with epoetin alfa at the start of chemotherapy is safe
and has beneficial effects on QOL, Hb levels, transfusions,
and clinical outcomes.
Comparative Studies of Erythropoietic Agents
in Patients with Cancer
Three head-to-head studies, one supported by Ortho
Biotech,38,39 and two supported by Amgen Inc.,40,41 compared
the efficacy of epoetin alfa and darbepoetin alfa in patients
with chemotherapy-related anemia. The Ortho Biotech study,
conducted by Waltzman et al.,38 was an open-label, random-
ized, multicenter, phase III study in patients with Hb 11 g/dL
or less. A total of 358 patients received either epoetin alfa
40,000 IU SC once weekly or darbepoetin alfa 200 mcg SC
once every 2 weeks for up to 16 weeks. Results for the
primary endpoint (percentage of patients with an increase in
Hb of 1 g/dL or more after 4 weeks of therapy) were based on
the first 305 patients completing 4 weeks of treatment (epo-
etin alfa, n  151; darbepoetin alfa, n  154). Results for all
other efficacy evaluations were based on the modified intent-
to-treat (MITT) population, defined as all patients who re-
ceived one or more doses of study drug and had one or more
postbaseline Hb or transfusions (epoetin alfa, n  175;
darbepoetin alfa, n  177). Considering the randomized
population (epoetin alfa, n 178; darbepoetin alfa, n 180),
patient characteristics at baseline were similar between the
epoetin alfa and darbepoetin alfa groups (mean age, 62.1 and
63.4 years; mean Hb, 10.2 and 10.1 g/dL; 26.4% and 26.1%
with lung cancer, respectively). A total of 33% of epoetin alfa
patients and 34% of darbepoetin alfa patients required a dose
increase to 60,000 IU once weekly or 300 mcg once every 2
weeks, respectively. A significantly greater proportion of
patients treated with epoetin alfa than darbepoetin alfa
achieved an Hb increase of 1 g/dL or more after 4 weeks of
treatment (47.0% versus 32.5%; p  0.0078). There was also
a greater proportion of patients in the epoetin alfa group
compared with the darbepoetin alfa group with an Hb in-
crease of 2 g/dL or more after 8 weeks of treatment (44.6%
versus 27.1%) and after 16 weeks of treatment (study end)
(57.7% versus 41.8%; p  0.004). Patients treated with
epoetin alfa had a greater mean increase in Hb at all assess-
ment points from week 3 to study end compared with darbe-
poetin alfa–treated patients (p  0.023),38 which contributed
to a higher area under the Hb change curve (Hb area under the
curve [AUC]) over time in the epoetin alfa group (14.23
versus 7.89 g/dL over 16 weeks).39 Based on these Hb AUCs
and a mean cumulative dose of 427,497 IU for epoetin alfa
and 1193 mcg for darbepoetin alfa, the calculated ratio at
which the agents were equally effective (dose conversion
ratio [IU epoetin alfa:mcg darbepoetin alfa]) was 199:1. This
dose conversion ratio indicates that a weekly epoetin alfa
dose of 40,000 IU was equivalent in efficacy to a weekly (not
an every-2-weeks) darbepoetin alfa dose of 200 mcg in this
study. Overall, 7.1% of epoetin alfa patients and 14.1% of
darbepoetin alfa patients received red blood cell transfusions
between day 29 (after 4 weeks of treatment) and day 56 (after
8 weeks of treatment) (p 0.0667).38 Mean improvements in
QOL from baseline to study end were observed in both
groups, and there was a positive correlation between changes
in QOL scores and changes in Hb.38
The first Amgen study, conducted by Schwartzberg et
al.,40 was a combined analysis of three identically designed,
open-label, multicenter studies. A total of 312 patients with
breast, gynecologic, or NSCLC and baseline Hb of 11 g/dL or
less were randomized to treatment with epoetin alfa 40,000
IU SC once weekly (n  155) or darbepoetin alfa 200 mcg
SC once every 2 weeks (n  157) for up to 16 weeks. Patient
n =
FIGURE 4. Linear Analog Scale Assessment
(LASA) Overall QOL scores during a randomized,
multicenter study evaluating the efficacy of im-
mediate versus delayed treatment with epoetin
alfa in patients with NSCLC receiving first-line
chemotherapy.37 QOL, quality of life; NSCLC,
non-small cell lung cancer. *Includes all control
patients, including 48 patients who received epo-
etin alfa because Hb decreased to less than 10
g/dL. †p  0.01 versus the immediate group.
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characteristics at baseline were generally similar between the
epoetin alfa and darbepoetin alfa groups (mean age, 61.7 and
58.7 years; mean Hb, 10.4 g/dL in both groups; 33% and 32%
with stage IIIb/IV NSCLC). The mean dose during the study
for darbepoetin alfa was 218.4 mcg once every 2 weeks and
for epoetin alfa was 39,949 IU once weekly. Although the
primary endpoint of the study was not to compare treatments
with respect to efficacy in correcting anemia, but rather to
validate the Patient Satisfaction Questionnaire for Anemia
(PSQ-An) tool, the authors concluded that the two agents
demonstrated similar Hb- and transfusion-related results. In
patients with NSCLC, the mean change in Hb from baseline
to the end of treatment was numerically higher in the epoetin
alfa group compared with the darbepoetin alfa group (1.3
g/dL versus 0.6 g/dL), as was the proportion of patients
achieving hematopoietic response (Hb increase 2 g/dL or
Hb 12 g/dL) (59% versus 49%). The proportion of patients
with NSCLC requiring transfusion from week 1 to study end
was lower in the epoetin alfa group than in the darbepoetin
alfa group (18% versus 27%). In the combined analysis of all
tumor subsets, the median time to reach target Hb 11 g/dL or
more was 1 week shorter in the epoetin alfa versus darbepo-
etin alfa group (4 weeks versus 5 weeks).40 Between-group
statistical comparisons were not reported for any of these
efficacy parameters.
The second Amgen study, conducted by Glaspy et al.,41
was a phase III, randomized, open-label, multicenter, nonin-
feriority study in patients with Hb 11 g/dL or less receiving
chemotherapy for 8 weeks or more for any nonmyeloid
malignancy. The dose regimens used in this study were
identical to those used in the other two head-to-head studies:
up to 16 weeks of epoetin alfa 40,000 IU SC once weekly
(n  603) or darbepoetin alfa 200 mcg SC once every 2
weeks (n  606). In a combined analysis of all tumor types
(mean baseline Hb: 10.2 g/dL in both groups), lung cancer
was the most common primary tumor type, present in ap-
proximately 25% of patients, and approximately 75% of
patients had a stage III or IV malignancy. The proportion of
patients transfused from week 5 to study end (primary end-
point) was 21% in the darbepoetin alfa group and 16% in the
epoetin alfa group. The mean increase in Hb from baseline to
final measurement was similar between groups (epoetin alfa,
1.6 g/dL; darbepoetin alfa, 1.4 g/dL). More than 90% of
patients in both groups achieved Hb 11 g/dL or more, al-
though the median time to achieving Hb 11 g/dL or more was
1 week shorter in the epoetin alfa group (5 weeks versus 6
weeks with darbepoetin alfa). As in the Schwartzberg et al.
study, no between-group statistical comparisons were re-
ported.
These head-to-head studies provide insight into the
magnitude and timing of response to epoetin alfa and darbe-
poetin alfa. Additional comparative studies powered to make
statistical comparisons between groups would be needed to
determine whether there is a significant difference in hema-
tologic outcomes during epoetin alfa or darbepoetin alfa
treatment in anemic patients with lung cancer. Based on a
review of the available data, current U.S. and European
evidence-based clinical practice guidelines for the treatment
of cancer- and chemotherapy-related anemia concluded that
both of these agents are equivalent in efficacy.29–31 Therefore,
until additional direct comparative data become available, the
decision as to which agent to use will need to be determined
on a case-by-case basis.
EFFECT OF ERYTHROPOIETIC THERAPY ON
SURVIVAL IN PATIENTS WITH CANCER
Preclinical studies have demonstrated antibody binding
to erythropoietin receptors on some tumor cell lines, includ-
ing lung cancer cells.42–45 Whether these antibodies are
specific and whether these receptors are functional remain
unclear. Two recent studies in the setting of head and neck
cancer46 and breast cancer47 demonstrated impaired survival
relative to placebo in mostly nonanemic patients with cancer
treated to Hb levels higher than currently recommended with
erythropoietic agents. In a prospective, double-blind, ran-
domized study of 939 patients with metastatic breast cancer
and baseline Hb 13 g/dL or less receiving first-line chemo-
therapy, patients received epoetin alfa or placebo for 12
months (even after chemotherapy was discontinued) to main-
tain Hb between 12 and 14 g/dL.47 The study was terminated
early because of significantly lower 12-month survival in the
epoetin alfa versus placebo group (70% versus 76%; p 
0.01). The survival difference was primarily due to an in-
crease in mortality during the first 4 months of the study. The
higher number of early deaths in the epoetin alfa group were
mainly attributed to disease progression (6% versus 3%) and
to thrombotic or vascular events (1% versus 0.2%). In a
separate double-blind, randomized study of 351 patients with
head and neck cancer and baseline Hb less than 12 g/dL
(men) or less than 13 g/dL (women) undergoing radiotherapy,
patients received epoetin beta or placebo to achieve a high
target Hb of 14 g/dL or more (women) or 15 g/dL or more
(men).46 Relative to placebo, the adjusted relative risk of
locoregional tumor progression in the epoetin beta group was
1.69 (95% confidence interval [CI]: 1.16, 2.47; p  0.007)
and the adjusted relative risk of death was 1.39 (95% CI:
1.05, 1.84; p  0.02). Certain imbalances in baseline char-
acteristics of particular subgroups also may have contributed
to the adverse survival effect of epoetin beta observed in this
study. For example, a subgroup analysis showed that treat-
ment with epoetin beta was associated with poorer survival
only among patients younger than 60 years old, those with
baseline Hb more than 11.0 g/dL, and those with advanced
disease or cancer of the hypopharynx. In patients with hypo-
pharyngeal cancer, a lower proportion of placebo-treated than
epoetin beta–treated patients had unfavorable baseline char-
acteristics (male gender, 86% versus 90%; smoker, 40%
versus 55%; baseline relapse, 7% versus 15%; and stage IV
disease, 70% versus 85%). Although the results of these trials
demonstrated a detrimental effect on survival in patients with
cancer randomized to the erythropoietic treatment arm, it
should be noted that both studies treated patients to Hb levels
higher than those currently recommended, and in the epoetin
beta study rapid increases in Hb of 2 g/dL in a 1-week period
were permitted. These factors may be associated with higher
rates of thrombovascular events than are normally seen with
epoetin alfa treatment to standard Hb levels.48
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Contrary to the negative survival findings reported in
two studies of erythropoietic agents in patients with can-
cer,46,47 other data suggest that treatment of anemia may
improve survival outcomes. This hypothesis was based on the
results from several studies indicating that anemia is an
independent prognostic factor for impaired survival in pa-
tients with lung cancer.23–26,49 A survival benefit of epoetin
alfa therapy was initially suggested by the results of a large,
randomized, double-blind, placebo-controlled study in pa-
tients with cancer receiving nonplatinum chemotherapy and
epoetin alfa. However, the study was not powered to evaluate
survival and did not control for factors that may influence
survival outcomes, such as disease stage, bone marrow in-
volvement, chemotherapy intensity, and disease progres-
sion.18
The potential effect of darbepoetin alfa on survival was
studied in 314 anemic (Hb 11 g/dL) patients with NSCLC
or SCLC receiving platinum chemotherapy.33 In this phase
III, double-blind, placebo-controlled, randomized study, the
median duration of progression-free survival was longer in
the darbepoetin alfa group (22 weeks [95% CI: 18, 31]) than
in the placebo group (20 weeks [95% CI: 17, 23]). This
apparent benefit on disease progression was predominantly in
the SCLC cohort. In these patients, the median progression-
free survival was 34 weeks (95% CI: 27–not able to be
estimated) in the darbepoetin alfa group versus 23 weeks
(95% CI: 16, 32) in the placebo group.50 In the overall
population (SCLC plus NSCLC patients), the median dura-
tion of survival was longer in the darbepoetin alfa group than
the placebo group (46 weeks [95% CI: 39, 53] versus 34
weeks [95% CI: 29, 39]).33
A more recent study evaluated the effects of epoetin
alfa on tumor response to chemotherapy and survival in
patients with SCLC.34 In this randomized, double-blind, pla-
cebo-controlled trial, patients with baseline Hb 14.5 g/dL or
less starting chemotherapy were assigned to epoetin alfa or
placebo, both administered until 3 weeks after completion of
the last cycle of chemotherapy. The overall tumor response
after completion of three chemotherapy cycles (primary end-
point) was 72% in the epoetin alfa group and 67% in the
placebo group (95% CI of the difference: 6%, 18%) and
after completion of chemotherapy was 60% and 56%, respec-
tively (95% CI of the difference:9%, 17%). Median overall
survival was similar in the epoetin alfa and placebo groups
(10.5 and 10.4 months, respectively), as was overall mortality
(91.7% and 87.8%, respectively; hazard ratio, 1.172; 95% CI:
0.887, 1.549; p 0.264). Although the results from this study
are considered preliminary, due to the study being terminated
early (after 224 of a projected 400 patients were accrued), the
results suggested no negative or positive effect of epoetin alfa
therapy on tumor response to chemotherapy or survival in the
patients evaluated.34
To further explore the safety of erythropoietic agents,
three separate meta-analyses were performed by the manu-
facturers of epoetin alfa, epoetin beta, and darbepoetin alfa
from studies in patients with cancer (solid tumors or hema-
tologic malignancies) and anemia treated according to global
prescribing guidelines.51–53 Results from these analyses,
which were presented at the U.S. Food and Drug Adminis-
tration Oncologic Drug Advisory Committee meeting in May
2004, demonstrated no deleterious effect of erythropoietic
agents on tumor progression or survival. The consensus of the
Oncologic Drug Advisory Committee was that the safety
concerns of erythropoietic agents appear to be a class effect
and that the current dosing recommendations for these agents
are adequate to minimize the risk of thrombovascular
events.54 The consensus also recommended that future studies
of erythropoietic agents in patients with cancer enroll a
homogeneous population with respect to tumor type and
cytotoxic therapy and be designed to detect clinically mean-
ingful decrements in tumor response, progression-free sur-
vival, and overall survival.
In an effort to optimize the safety of erythropoietic
therapy in patients with cancer, the NCCN and EORTC
guidelines recommend not exceeding a target Hb level of 12
g/dL during treatment,30,31 and the NCCN guidelines recom-
mend reducing the dose of epoetin alfa or darbepoetin alfa by
25% if Hb increases more than 1 g/dL in a 2-week period.31
The NCCN guidelines also recommend withholding therapy
if Hb exceeds 12 g/dL, with reinitiation at a 25% dose
reduction if Hb decreases to less than 12 g/dL. Further, the
EORTC guidelines advise against the prophylactic use of
erythropoietic agents to prevent anemia in patients undergo-
ing cancer treatment who have normal baseline Hb levels.30
Both panels concur that there are insufficient data to deter-
mine the effect of erythropoietic therapy on survival and that
more rigorous trials are needed to evaluate survival outcomes
in this setting. An ongoing randomized phase III trial is
currently being conducted to determine the efficacy of che-
motherapy and radiation therapy with or without epoetin alfa
in treating patients with stage IIIA or stage IIIB NSCLC.55
Although the primary endpoint of this study is the efficacy of
epoetin alfa in maintaining Hb (entry Hb, 11–15 g/dL),
patients will also be evaluated for time to local and systemic
progression, tumor response, and overall survival as second-
ary endpoints. An additional randomized, double-blind, pla-
cebo-controlled study is currently recruiting patients with
previously untreated extensive-stage SCLC scheduled to un-
dergo treatment with platinum plus etoposide chemotherapy
with or without darbepoetin alfa.56 In addition to change in
Hb (entry Hb, 9–13 g/dL), survival is a primary outcome of
this study. It is hoped that results from these ongoing studies
will help provide further information on the effect of eryth-
ropoietic therapy on survival and tumor response to chemo-
therapy in patients with lung cancer undergoing cytotoxic
therapy.
EFFECT OF ERYTHROPOIETIC THERAPY ON
COGNITIVE FUNCTION IN PATIENTS WITH
CANCER
It is not fully known why cognitive impairment devel-
ops in some patients with cancer, although the cause is likely
multifactorial, including factors such as the underlying dis-
ease itself, cancer treatment (chemotherapy, radiation ther-
apy), and untreated anemia.57–60 Studies have suggested that
cognitive impairment in patients with lung cancer occurs at
least partially as a result of the disease itself. This was shown
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in a study of 32 patients with SCLC who underwent neuro-
logic and neuropsychological tests before and during four
separate follow-up visits until 5 months after receiving pro-
phylactic cranial irradiation.61 Although no deterioration of
cognitive function was evident either before or during treat-
ment with chemotherapy or after prophylactic cranial irradi-
ation, there was a significant (p  0.001) difference in
pretreatment performance on neuropsychological tests be-
tween patients with SCLC and age-matched controls. A
separate study evaluating the effects of combined chemother-
apy and thoracic radiation therapy on cognitive function in
patients with SCLC showed that cognitive deficits in verbal
memory, frontal lobe executive function, and motor coordi-
nation were apparent before treatment, with no differences
between treated and untreated patients.62
Because anemia has been implicated as one potential
cause of cognitive impairment in patients with cancer, the
relationship between changes in Hb and cognitive function
were evaluated in 77 patients with various cancers (33% with
lung cancer).63 The majority of patients in this study did not
receive recombinant human erythropoietin (94%) or blood
transfusion (90%). Cognitive tests were administered twice,
before treatment and before the start of the fourth treatment
cycle. Mean Hb decreased by 1.1 g/dL from baseline to the
fourth treatment cycle (p  0.0001). Forty-nine patients
experienced a decrease in Hb to 12 g/dL or less (29% of these
patients had lung cancer). In these patients, greater decreases
in Hb were significantly (p  0.05) related to more negative
changes in performance on measures of complex executive
cognitive ability.
Although no published data evaluating the effect of
epoetin alfa therapy on cognitive function in patients with
lung cancer have been published, such studies have been
reported in patients with other tumor types.64,65 In a double-
blind, randomized, placebo-controlled study that enrolled
patients with breast cancer and baseline Hb of 9 to 14 g/dL
receiving anthracycline-based adjuvant or neoadjuvant che-
motherapy for 12 weeks, 94 assessable patients received
either epoetin alfa 40,000 IU or placebo administered SC
once weekly.64 Cognitive function was assessed by the Ex-
ecutive Interview 25. From baseline to cycle 4, the mean
change in Hb was 0.8 g/dL in the epoetin alfa group and2.1
g/dL in the placebo group. During the same time period, the
mean change in Executive Interview 25 score (decrease in
score relates to improvement in cognitive function) was1.3
in the epoetin alfa group and 0.3 in the placebo group, and
the proportions of patients with 1 or more SD improvement in
cognitive function were 18.2% and 2.3%, respectively.64
These initial results suggest that epoetin alfa may improve or
prevent deterioration in cognitive function in patients with
cancer, either through correction of anemia or by other
mechanisms.
The impact of anemia correction on cognitive function
in anemic (Hb 12 g/dL) patients with hematologic malig-
nancies (multiple myeloma, non-Hodgkin’s lymphoma,
Hodgkin’s disease, or chronic lymphocytic leukemia) receiv-
ing chemotherapy (planned enrollment, n  1000) was re-
cently assessed in a preliminary analysis of 383 patients
enrolled in an international, prospective, open-label, multi-
center study.65 Patients were treated with epoetin alfa 40,000
IU SC once weekly for up to 24 weeks and cognitive function
was assessed by the Cognitive Drug Research (Berkshire,
UK) Computerised Cognitive Assessment System. Patients
demonstrated poorer cognitive function at baseline compared
with healthy, age-matched controls. From baseline to week
24, speed of memory improved by 359 msec, an 8% improve-
ment in the combined speed of memory scores (working
memory, word recognition, picture recognition). Improve-
ments in cognitive function were associated with an increase
in Hb from 10.5 g/dL at baseline to approximately 12 g/dL
beginning at weeks 8 to 12 and sustained through week 24.65
These data suggest that decreases in Hb are associated
with deterioration in cognitive function. However, additional
studies are needed to further document the relationship be-
tween anemia and cognitive function. In addition, although a
few studies have demonstrated that anemia treatment with
epoetin alfa may help maintain or improve cognitive function
in patients with breast cancer or hematologic malignancies
undergoing chemotherapy, additional studies of erythropoi-
etic stimulating agents in patients with other tumor types,
including lung cancer, are needed.
CONCLUSION
Anemia is prevalent and is associated with increased
need for transfusion, impaired QOL, and poorer survival in
patients with lung cancer. Despite these detrimental out-
comes, anemia is substantially undertreated, with more than
half of anemic patients not receiving any treatment for ane-
mia. The clinical benefit of erythropoietic therapy in increas-
ing Hb, decreasing transfusions, and improving QOL in
patients with cancer has been demonstrated in several large
studies. Direct head-to-head studies indicate that epoetin alfa
is at least as effective as darbepoetin alfa in correcting anemia
in patients with cancer. Preliminary results from a recently
completed study indicate that initiation of epoetin alfa ther-
apy at the start of chemotherapy effectively maintains Hb
levels in patients with advanced NSCLC and baseline Hb of
11 g/dL or more to less than 15 g/dL. Final results of this
study will provide further insight into the clinical utility and
safety of epoetin alfa in this setting. Currently, patients with
anemia and lung cancer should be managed according to
clinical practice guidelines, with erythropoietic therapy con-
sidered for patients with Hb 11 g/dL or less and treatment
adjusted accordingly to maintain an optimal Hb target of 12
g/dL. Additional studies in patients with lung cancer are
needed to further evaluate the relationship between Hb levels
and correction of anemia on cognitive function and survival.
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